Binarly, a leading innovator in software supply chain security, today announced that it has been granted U.S. Patent No. US 12,236,262 B1 for its groundbreaking "Machine Learning Technique for ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion will also hold a webinar on Thursday, February 6th at 6:30am MT/8:30am ET/1:30pm GMT to present the Phase 2 data. The webinar will be broadcast from Recursion’s X (formerly Twitter ...

In a phone call last week, "Putin and Trump agreed on the necessity of leaving behind absolutely abnormal relations," Sergei Lavrov said, adding that "the presidents agreed dialogue needs to be ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

Secretary of State Marco Rubio’s meeting with his Russian counterpart in Riyadh on Tuesday marked a major shift in U.S. relations with the country, ending a policy of isolation imposed after ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Once again, the eastern Congolese city of Goma has fallen to the Rwanda-backed ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

explaining that the EU shouldn’t take into account its trade relations with the US when deciding on DMA probes on Big Tech. In the midst of Donald Trump's trade offensive against the EU ...